Educational reference, not medical advice. This page summarizes information from published research and regulatory filings for educational purposes. It is not a recommendation to use any compound and should not replace guidance from a licensed healthcare provider. Most peptides discussed here are not approved for the uses described.
What it is
This is a commercial pre-mixed combination of three peptides — BPC-157, TB-500, and KPV — supplied by research-peptide vendors as a single lyophilized vial. The product is less common than the GHK-Cu-containing Glow or Klow blends but appears periodically under names such as "Gut + Tissue Blend" or "BPC/TB/KPV Triplet." Ratios vary by supplier; a typical preparation co-lyophilizes the three peptides in approximately equal milligram amounts.
The pairing is marketed within research-peptide channels for protocols that aim at both tissue repair (driven by the component literature on BPC-157 and TB-500) and gut-related anti-inflammatory research (driven by the KPV literature on colitis models). The blend itself has no clinical evaluation as a single product.
History
The three peptides have separate research histories:
- BPC-157 — characterized by the Sikiric laboratory at the University of Zagreb starting in 1991, originally as a tool for studying gastric ulcer healing.
- TB-500 — the 17–23 fragment of Thymosin Beta-4, originally used in equine veterinary medicine and later in the human research-peptide market.
- KPV — α-MSH(11-13), characterized in the late 1990s and 2000s as the minimal anti-inflammatory fragment of α-melanocyte-stimulating hormone, with most published evidence in rodent colitis models.
The combined product emerged in research-peptide retail in the early 2020s. No peer-reviewed publication describes the three-peptide blend, its pharmacokinetics, or its interactions.
Regulatory status
The blend has no regulatory approval. BPC-157 was placed in FDA 503A Category 2 in November 2023, restricting compounding in the United States. TB-500 has been on the WADA prohibited list since 2011. KPV has no FDA-approved use in any formulation. The combined product is supplied through research-chemical suppliers labeled not for human use.
How researchers describe its action
Each component is described separately in the published literature:
- BPC-157 is reported in preclinical work to modulate nitric oxide signaling, upregulate VEGFR2, and accelerate healing of tendon, gut, and vascular tissue in rodent models.
- TB-500 is described as a promoter of cell migration into wound beds via its actin-binding sequence, with downstream effects on angiogenesis and inflammation.
- KPV is described as a suppressor of NF-κB signaling in macrophages and intestinal epithelium, with antimicrobial activity demonstrated in vitro at micromolar concentrations. Its anti-inflammatory activity is documented in rodent colitis after oral and parenteral administration.
Whether the three peptides interact pharmacologically when co-injected has not been studied.
Half-life and dosing intervals
Half-lives of the three components:
- KPV: approximately 20–30 minutes.
- BPC-157: 15–30 minutes.
- TB-500: 1.5–3 hours.
Observational protocols described in research-peptide channels typically involve subcutaneous injection once daily, with total per-injection mass in the 1–3 mg range across all three peptides. None of these regimens is derived from a controlled clinical trial.
Reconstitution example
A 15 mg vial (5 mg each of the three peptides) reconstituted with 2 mL of bacteriostatic water yields a total peptide concentration of 7.5 mg/mL. On a 1 mL U-100 insulin syringe, 10 units (0.10 mL) delivers 0.75 mg total peptide mass, split across the three components according to the supplier's ratio.
Vial's calculator handles total-mass-to-syringe-unit math; per-component mass is only as accurate as the labeled ratio, which is generally not independently verified by a third-party assay.
What to know
- No combined clinical data. No peer-reviewed study has evaluated the three-peptide blend as a single product. All evidence applies to individual components in isolation.
- Component regulatory status. BPC-157 cannot legally be compounded for U.S. patients; TB-500 is WADA-banned; KPV is unapproved for any therapeutic use.
- Storage. Refrigerate lyophilized vials. After reconstitution, refrigerate and use within four weeks or less, matched to the shortest-stable component.
- Reported side effects. Component user reports describe injection-site irritation as the most common observation, with transient headaches reported for BPC-157 and lethargy reported for high-dose TB-500. No controlled human safety profile exists for the combined product.
Sources
- 1.Sikiric P et al. (2018). Brain-gut Axis and Pentadecapeptide BPC 157. Current Neuropharmacology.
- 2.Goldstein AL et al. (2012). Thymosin β4: a multifunctional regenerative peptide. Expert Opinion on Biological Therapy.
- 3.Dalmasso G et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology.
- 4.Bettenworth D et al. (2011). Anti-inflammatory effect of the α-MSH tripeptide KPV in experimental colitis. Inflammatory Bowel Diseases.
- 5.FDA 503A Bulk Drug Substances list — Category 2 (November 2023, BPC-157).